First-line nivolumab (anti-PD-1) monotherapy in advanced NSCLC: the story of immune checkpoint inhibitors and "the sorcerers apprentice".

MLA

Schmid-Bindert, Gerald, and Tao Jiang. “First-Line Nivolumab (Anti-PD-1) Monotherapy in Advanced NSCLC: The Story of Immune Checkpoint Inhibitors and ‘the Sorcerers Apprentice.’” Translational Lung Cancer Research, vol. 4, no. 3, June 2015, pp. 215–16. EBSCOhost, https://doi.org/10.3978/j.issn.2218-6751.2015.01.12.

APA

Schmid-Bindert, G., & Jiang, T. (2015). First-line nivolumab (anti-PD-1) monotherapy in advanced NSCLC: the story of immune checkpoint inhibitors and “the sorcerers apprentice.” Translational Lung Cancer Research, 4(3), 215–216. https://doi.org/10.3978/j.issn.2218-6751.2015.01.12

Chicago

Schmid-Bindert, Gerald, and Tao Jiang. 2015. “First-Line Nivolumab (Anti-PD-1) Monotherapy in Advanced NSCLC: The Story of Immune Checkpoint Inhibitors and ‘the Sorcerers Apprentice.’” Translational Lung Cancer Research 4 (3): 215–16. doi:10.3978/j.issn.2218-6751.2015.01.12.